Peng Fang, Yuan Hao, Zhou Yi-Feng, Wu Si-Xian, Long Zhen-Yi, Peng Ya-Meng
Department of Clinical Laboratory, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, 410005, People's Republic of China.
Operating Room, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, 410005, People's Republic of China.
Int J Gen Med. 2022 Jun 23;15:5763-5773. doi: 10.2147/IJGM.S362359. eCollection 2022.
We aimed to explore the clinical diagnostic value of combined detection via protein induced by vitamin K absence or antagonist II (PIVKA-II), alpha-fetoprotein (AFP), and D-dimer (D-D) in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC).
We analyzed PIVKA-II, AFP, and D-D levels in 291 subjects comprising liver cirrhosis (LC) patients (n = 143) and HCC patients (n = 148). Receiver operating characteristic (ROC) curves were used to analyze and compare the clinical diagnostic value of the three biomarkers for HBV-related HCC alone and in combination.
The levels of PIVKA-II, AFP, and D-D were positively correlated with tumor size in HCC patients. The levels of PIVKA-II and AFP in early-stage HCC, advanced HCC, HBV DNA+ HCC, and HBV DNA- HCC patients were higher than those in LC patients, while the levels of D-D were lower. The area under the curve for combined detection was greater than that for single-index detection in early-stage HCC, advanced HCC, HBV DNA+ HCC, and HBV DNA- HCC patients.
D-D may be a useful biomarker for the diagnosis of HBV-related HCC. The combined detection of PIVKA-II, AFP, and D-D had better diagnostic value for different types of HCC than the detection of individual biomarkers.
我们旨在探讨维生素K缺乏或拮抗剂II诱导蛋白(PIVKA-II)、甲胎蛋白(AFP)和D-二聚体(D-D)联合检测在乙型肝炎病毒(HBV)相关肝细胞癌(HCC)中的临床诊断价值。
我们分析了291名受试者的PIVKA-II、AFP和D-D水平,这些受试者包括肝硬化(LC)患者(n = 143)和HCC患者(n = 148)。采用受试者操作特征(ROC)曲线分析和比较这三种生物标志物单独及联合检测对HBV相关HCC的临床诊断价值。
HCC患者中PIVKA-II、AFP和D-D水平与肿瘤大小呈正相关。早期HCC、晚期HCC、HBV DNA阳性HCC和HBV DNA阴性HCC患者的PIVKA-II和AFP水平高于LC患者,而D-D水平较低。在早期HCC、晚期HCC、HBV DNA阳性HCC和HBV DNA阴性HCC患者中,联合检测的曲线下面积大于单指标检测。
D-D可能是诊断HBV相关HCC的有用生物标志物。与单个生物标志物检测相比,PIVKA-II、AFP和D-D联合检测对不同类型的HCC具有更好的诊断价值。